ArticleEpilepsia2026
C1q neutralization during epileptogenesis attenuates complement-mediated synaptic elimination and epileptiform activity.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Targeting the Complement-Microglia Axis for Neuroprotection in Pediatric Epilepsy.Biomedicines · 2026Review
- Temporal profiling of hippocampal astrocyte reactivity reveals persistent GFAP cleavage and complement C3 association after status epilepticus.Brain structure & function · 2026Article
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
- Microglia-Mediated Disinhibition: Taking the Brakes off Epileptic Networks.Epilepsy currents · 2026Article
- Review
- Targeting microglial C1q alleviates blood-brain barrier disruption in the thalamus after cortical infarction.Journal of neuroinflammation · 2026Article
- C1q neutralization during epileptogenesis attenuates complement-mediated synaptic elimination and epileptiform activity.Epilepsia · 2026Article
- Microglial Maturation and Functional Heterogeneity: Mechanistic Links to Neurodevelopmental Disorders.International journal of molecular sciences · 2026Review
- Artificial intelligence for automated detection of interictal epileptiform discharges: methodological progress, clinical evaluation, and neurodevelopmental context.Frontiers in cell and developmental biology · 2026Review
- Microglial pathological synaptic pruning in epilepsy: pathophysiology and therapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAccumulating evidence indicates that aberrant C1q-C3 complement signaling in microglia and astrocytes drives synaptic dysfunction and neuronal loss. C1q-mediated synaptic dysfunction disrupts neuronal circuitry balance and can lead to network hyperexcitability in epilepsy. However, the therapeutic potential of C1q inhibition remains unclear. This study aimed to delineate whether blocking C1q-driven pathways at critical times can effectively prevent further synaptic loss and attenuate epileptiform activity in a mouse model of epilepsy.
methodsMicroglial C1q and astrocytic C3 expression was examined in hippocampal CA1 and CA3 regions at acute (1 day), subacute (7, 14 days), and chronic (5 weeks) phases following pilocarpine-induced status epilepticus (SE) in mice. To evaluate the role of C1q activation, a C1q-neutralizing antibody or isotype control immunoglobulin G antibody was administered into cisterna magna at 7 days post-SE. During the chronic phase, glial reactivity, dendritic spine density, and epileptiform activity were assessed by immunostaining, Golgi staining, and electroencephalography (EEG) recording. After exclusions, 58 mice were included in the study.
resultsC1q expression was elevated during the subacute phase (7 and 14 days post-SE) in CA1 and CA3 regions; astrocytic C3 expression increased in CA1 and persisted chronically. C1q-neutralizing antibody administration at 7 days post-SE, a time point characterized by prominent C1q upregulation, attenuated microglial synaptic phagocytosis, and astrocytic C3 activation. This intervention preserved dendritic spine density and ultimately reduced interictal spike frequency in EEG recordings in the chronic phase. SIGNIFICANCE: Our findings demonstrate that C1q acts as an upstream mediator of complement-driven neuronal loss during epileptogenesis. C1q blockade interrupted the pathogenic cascade involving microglial engulfment and astrocytic C3 upregulation, thereby preserving synaptic and neuronal integrity and reducing interictal spike activity. Our study highlights the therapeutic potential of C1q inhibition, which can provide multifaceted benefits by mitigating neuroinflammation, improving synaptic integrity, and reducing epileptiform activity during epileptogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.